Advancing
cannabinoid-based
and targeted therapies
for the treatment of
cancer
Pascal Biosciences is dedicated to improving the lives of patients suffering from life-threatening diseases such as glioblastoma and other intractable cancers. We are developing novel cannabinoid-based small molecules and targeted antibodies, focusing on cancers for which there are no adequate therapies.
PAS-403 for Glioblastoma
PAS-403 is a cannabinoid-based small molecule that utilizes a unique mechanism of action to kill cancer cells. Clinical trials are targeted to begin in 2021.
PAS-393 for Cancer
PAS-393 is a cannabinoid that makes cancers visible to the immune system.
Latest News
Pascal Biosciences Announces Private Placement and Potential Transaction with SŌRSE Technology for Cannabinoid Research Programs
March 10, 2020
Read More